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were 71%, 67%, 66%, 64%, 63%, 60%, 52% and 23% respectively. The
persistence-adherence index at two year was 66% for ARAs, 63% for
amlodipine, 62% for -blockers, 61% for other CCBs, 60% for ACE
inhibitors, 51% for hydrochorothiazide, 50 % for other diuretics and 32%
for chlorthalidone.
Conclusion: Persistence and adherence to treatment are essential to
treatment success and varied substantially between the different thera-
peutic options. Results of this study indicate that, in a real life setting,
patients are significantly less compliant to diuretics than to any other
antihypertensive agents.
Key Words: Treatment Compliance, Antihypertensive Drugs, Drug Da-
tabases Analyses
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EFFECTIVE BLOOD-PRESSURE CONTROL WITH
VALSARTAN/HCTZ COMBINATION THERAPY IN
PATIENTS WITH MODERATE TO SEVERE SYSTOLIC
HYPERTENSION: THE VALOR TRIAL
Yves Lacoursiere, Daniel Hebert, Linda Assouline, Bonita Rehel,
Yasser Khder. Director Hypertension Unit, Centre Hospitalier
Universite Laval, Sainte Foy, QC, Canada; Medical Department,
Novartis Pharma Canada inc., Dorval, QC, Canada; Clinical
Development & Medical Affairs, WSJ-202.228A Novartis, Basel,
Switzerland.
Background: Increasing evidence shows that combination therapy with
at least two antihypertensive agents is needed to achieve appropriate
blood-pressure (BP) control in a large part of the hypertensive popula-
tion. One of the most appealing combinations is that of adding a diuretic
to an angiotensin-receptor blocker (ARB).
Methods: We studied the effects on sitting systolic BP of the combi-
nations valsartan (V; an ARB) 160 mg  HCTZ 12.5 mg and V160
mg  HCTZ 25 mg od, compared with monotherapy V160 mg od.
Treatment-naive and previously treated patients (N767) with moderate
to severe systolic hypertension (SBP 160 mm Hg and 200 mmHg)
and with or without co-morbidities, were randomised (after a 2-week
washout if previously treated and a 2 week placebo run-in period) to
either V80 od (monotherapy group) or V160 od (combination groups) for
4 weeks, with force-tration to V160 mg, V160/HCTZ 12.5 od or V160/
HCTZ 25 od for an additional 4 weeks. Endpoints were change in SBP
between V160 and V160/HCTZ 25 and between V160/HCTZ 12.5 and
V160; changes in DBP between groups, response rates and tolerability.
Results: As shown in the Table, all treatments were highly effective
and there were additional SBP and DBP reductions in the combination
groups. Responder rates were above 50% in all groups and reached 75%
in the V160/HCTZ 25 group. Rates of adverse events did not differ
significantly between monotherapy and combination therapies.
Conclusions: V160 mg od is safe and effective in patients with
moderate to severe systolic hypertension. Adding HCTZ 12.5 or 25 mg
provides significant additional reductions in systolic and diastolic BP and
increases responder rates compared with V160 mg monotherapy, with
maintained excellent tolerability.
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EFFECTS ON BLOOD PRESSURE, NITRIC OXIDE
URINARY EXCRETION AND ON eNOS PROTEIN
EXPRESSION BY NEVIBOLOL AND METOPROLOL
IN SPONTANEOUSLY-HYPERTENSIVE RATS
Bjoern Lemmer, Kirsten Meier, Stefan Gorbey. Institute of Pharmacology
and Toxicology, University of Heidelberg, Mannheim, Germany.
The acute effects of Nebivolol (NEB), a beta-blocker which activates the
NO-pathway, and Metoprolol (MET) on nitric oxide (NOx) urinary excre-
tion, blood pressure (BP) and on protein expression of endothelial nitric
oxide synthase (eNOS) in thoracic/abdominal aortae were studied in spon-
taneously hypertensive rats (SHR). NOx excretion was studied by sampling
urine every 12 h after i.p. inj. of NEB (30mg/kg) or MET (30mg/kg) at 7 and
19h. BP was measured by telemetry after i.p. inj. of NEB (3,10,30 mg/kg) or
MET (1.98, 6.59, 30, 100 mg/kg) at 7 and 19h. Thoracic and abdominal
aortae were withdrawn 24 hours after NEB (30 mg/kg) injection at 7h to
determine eNOS protein expression by Western blot.
NEB significantly increased NOx excretion, most marked 12–24h after
drug dosing, whereas MET had no effect. Effects of MET and NEB on BP
were only dose-dependent when given at 19h: Max. was reached by MET
after 30 min (21mmHg) and by NEB after 3 hours (30mmHg). NEB
lowered BP for several days, MET only for some hours. eNOS protein
expression was not affected by NEB: control vs NEB in thoracic (OD:
85.8  18.3 and 94.2  19.8, resp) in abdominal aortae (OD: 113.2 .
11.3 and 125.3  11.7, resp). Thus, NEB in contrast to MET affected the
NO-pathway by enhancing NOx production, eNOS protein expression
was not influenced. Increased NOx excretion by NEB was completely
prevented by the NO-synthase inhibitor L-NAME. The increased NOx
excretion must be due to increased activity of eNOS. The two beta-
blockers also vary in onset and duration of decreasing BP. The long-
lasting effect of NEB may be due to active metabolites.
Support: Berlin-Chemie, Berlin, Germany
Key Words: Nebivolol and Metoprolol, Nitric Oxide, Spontaneously-
Hypertensive Rats
P-227
EFFECTS OF IRBESARTAN ON PLATELET
AGGREGATION AND MARKERS OF INFLAMMATION
IN HYPERTENSIVE PATIENTS WITH AND WITHOUT
ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
Pavel J Levy, Ronald D Smith, Bridget Brosnihan, John Owen, Mark
Espeland, Carlos M Ferrario. Hypertension and Vascular Disease
Center, Wake Forest University School of Medicine, Winston-Salem,
NC; Hematology and Oncology, Wake Forest University School of
Medicine, Winston-Salem, NC; Public Health Sciences, Wake Forest
University School of Medicine, Winston-Salem, NC.
Clinically evident atherosclerotic cardiovascular disease (ASCVD) is a
pro-inflammatory state associated with increased platelet aggregability
(PAGG) and activation of the renin angiotensin system.
Objectives: We hypothesize that: a) in hypertensive patients a selec-
tive angiotensin II AT1 receptor antagonist Irbesartan (IRB) in addition to
its hypotensive effect may also contribute to reduction of PAGG and of
plasma markers of inflammation; b) these effects of IRB are different in
patients with and without ASCVD.
Table 1
V160 V160/HCTZ12.5 V160/HCTZ25
N 261 254 252
Male/female 130/131 141/113 140/112
Mean age 60.4 (10.6) 60.8 (11.5) 60.7 (11.6)
Baseline mean SBP/DBP 167.9 (8.0)/93.2 (8.9) 167.4 (8.3)/93.4 (9.6) 167.2 (7.9)/93.7 (8.8)
Mean change SBP/DBP 20.7 (15.7)/6.6 (8.9) 27.9 (13.8) */10.2 (7.7)* 28.3 (13.1) */10.1 (7.8)*
Response rate¥ 56.9% 74.4%* 75%*
Any AE (monotherapy
phase/combination
phase)
37.3%/27.5% 32.1%/28.6% 32.8%/34.0%
Values in brackets are SD. * P 0.05 vs V160; ¥ SBP 140 or decrease in SBP
20 mmHg and/or DBP90 mmHg
NOx urine excretion after Nebivolol and Metoprolol in SHR
Drug dosing at
7h
Drug dosing at
19h
Urins sampling
from 19-7h
ANOVA Urine sampling
from 7-19h
ANOVA
Control (n  5) 0.9 / 0.1 p  0.001† 0.5 / 0.1 p  0.01†
NEB (n  5) 4.9 / 1.0 p  0.001‡ 3.0 / 0.6 p  0.01‡
MET (n  5) 1.0 / 0.1 0.5 / 0.0
Means / SEM, expressed as moles, † Control vs NEB, ‡ NEB vs MET
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